182 related articles for article (PubMed ID: 28476269)
1. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
Finlay AK; Ellerbe LS; Wong JJ; Timko C; Rubinsky AD; Gupta S; Bowe TR; Burden JL; Harris AHS
J Subst Abuse Treat; 2017 Jun; 77():38-43. PubMed ID: 28476269
[TBL] [Abstract][Full Text] [Related]
2. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS
J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
Harris AHS; Ellerbe L; Reeder RN; Bowe T; Gordon AJ; Hagedorn H; Oliva E; Lembke A; Kivlahan D; Trafton JA
Psychol Serv; 2013 Nov; 10(4):410-419. PubMed ID: 23356858
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
Harris AH; Bowe T; Hagedorn H; Nevedal A; Finlay AK; Gidwani R; Rosen C; Kay C; Christopher M
Addict Sci Clin Pract; 2016 Sep; 11(1):15. PubMed ID: 27633982
[TBL] [Abstract][Full Text] [Related]
5. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Williams EC; Matson TE; Harris AHS
Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
[TBL] [Abstract][Full Text] [Related]
6. Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics.
Williams EC; Achtmeyer CE; Young JP; Berger D; Curran G; Bradley KA; Richards J; Siegel MB; Ludman EJ; Lapham GT; Forehand M; Harris AHS
J Gen Intern Med; 2018 Mar; 33(3):258-267. PubMed ID: 29086341
[TBL] [Abstract][Full Text] [Related]
7. Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes.
Hagedorn HJ; Wisdom JP; Gerould H; Pinsker E; Brown R; Dawes M; Dieperink E; Myrick DH; Oliva EM; Wagner TH; Harris AHS
Addict Sci Clin Pract; 2019 Jul; 14(1):24. PubMed ID: 31291996
[TBL] [Abstract][Full Text] [Related]
8. Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration.
Taylor E; Timko C; Harris AHS; Yu M; Finlay AK
Addict Sci Clin Pract; 2019 Jan; 14(1):1. PubMed ID: 30602392
[TBL] [Abstract][Full Text] [Related]
9. VA residential substance use disorder treatment program providers' perceptions of facilitators and barriers to performance on pre-admission processes.
Ellerbe LS; Manfredi L; Gupta S; Phelps TE; Bowe TR; Rubinsky AD; Burden JL; Harris AH
Addict Sci Clin Pract; 2017 Apr; 12(1):10. PubMed ID: 28372579
[TBL] [Abstract][Full Text] [Related]
10. Group management of pharmacotherapy for alcohol dependence: feasibility and impact on adoption.
Robinson S; Bowe T; Harris AH
J Subst Abuse Treat; 2013; 45(5):475-7. PubMed ID: 23932227
[TBL] [Abstract][Full Text] [Related]
11. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
12. Geographic differences in receipt of addictions treatment in a national sample of patients with alcohol use disorders from the U.S. Veterans Health Administration.
Edmonds AT; Bensley KM; Hawkins EJ; Williams EC
Subst Abus; 2021; 42(4):559-568. PubMed ID: 32821028
[No Abstract] [Full Text] [Related]
13. Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment.
Williams EC; Young JP; Achtmeyer CE; Hendershot CS
J Subst Abuse Treat; 2016 Nov; 70():14-20. PubMed ID: 27692183
[TBL] [Abstract][Full Text] [Related]
14. Alcohol-related and mental health care for patients with unhealthy alcohol use and posttraumatic stress disorder in a National Veterans Affairs cohort.
Chen JA; Owens MD; Browne KC; Williams EC
J Subst Abuse Treat; 2018 Feb; 85():1-9. PubMed ID: 29291765
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
Harris AH; Kivlahan DR; Bowe T; Humphreys KN
Psychiatr Serv; 2010 Apr; 61(4):392-8. PubMed ID: 20360279
[TBL] [Abstract][Full Text] [Related]
16. Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.
Del Re AC; Gordon AJ; Lembke A; Harris AH
Addict Sci Clin Pract; 2013 Jul; 8(1):12. PubMed ID: 23835352
[TBL] [Abstract][Full Text] [Related]
17. Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
Walker JR; Korte JE; McRae-Clark AL; Hartwell KJ
J Stud Alcohol Drugs; 2019 Sep; 80(5):572-577. PubMed ID: 31603760
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
[TBL] [Abstract][Full Text] [Related]
19. [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
Gahr M; Kölle MA; Schönfeldt-Lecuona C
Nervenarzt; 2013 May; 84(5):584-9. PubMed ID: 22892944
[TBL] [Abstract][Full Text] [Related]
20. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
